Crely
Develops a multimodal continuous monitoring and clinical-intelligence platform for postoperative care. The platform combines a single wearable that captures multiple physiological signals with signal processing, patient-specific baselining, longitudinal analysis, and prioritized alerting to extend clinical visibility across ICU, ward, and recovery at home. Current development is at retrospective proof-of-concept with prospective validation under way; the platform is investigational and not regulatory-cleared.
Industries
Nr. of Employees
small (1-50)
Products
Wearable multimodal physiological sensor
A small, low-profile wearable that continuously measures multiple physiological modalities (tissue oxygenation, bioimpedance, ECG, skin temperature, motion) for use in hospital and home settings.
Cloud-based clinical-intelligence platform
Cloud infrastructure and analytics that quality-checks signals, creates patient-specific baselines, performs longitudinal analysis, and surfaces prioritized alerts and dashboards to care teams.
Crely AI-based Early Warning System and Wearable Device
An AI-based early warning system combined with a non-invasive wearable sensor for continuous monitoring of patient biomarkers around the wound to predict and detect surgical site infections (SSIs) for clinical intervention.
CrelyCOMPASS
A multimodal monitoring and clinical-intelligence platform designed to help care teams identify emerging postoperative complications earlier across ICU, ward, and recovery at home.
Wearable multimodal physiological sensor
A small, low-profile wearable that continuously measures multiple physiological modalities (tissue oxygenation, bioimpedance, ECG, skin temperature, motion) for use in hospital and home settings.
Cloud-based clinical-intelligence platform
Cloud infrastructure and analytics that quality-checks signals, creates patient-specific baselines, performs longitudinal analysis, and surfaces prioritized alerts and dashboards to care teams.
Crely AI-based Early Warning System and Wearable Device
An AI-based early warning system combined with a non-invasive wearable sensor for continuous monitoring of patient biomarkers around the wound to predict and detect surgical site infections (SSIs) for clinical intervention.
CrelyCOMPASS
A multimodal monitoring and clinical-intelligence platform designed to help care teams identify emerging postoperative complications earlier across ICU, ward, and recovery at home.
Services
Services to assess populations, design monitoring workflows and alerts, run pilots or validation studies, evaluate outcomes, and scale programs within hospitals.
Provision of study designs, cohort details, methods, and full development-stage performance under evidence briefings for clinical and partner conversations.
Services to assess populations, design monitoring workflows and alerts, run pilots or validation studies, evaluate outcomes, and scale programs within hospitals.
Provision of study designs, cohort details, methods, and full development-stage performance under evidence briefings for clinical and partner conversations.
Expertise Areas
- Postoperative continuous monitoring
- Biosignal processing and feature engineering
- Machine-learning risk modeling and pattern recognition
- Clinical validation and prospective study design
Key Technologies
- Near-infrared spectroscopy (NIRS) tissue oximetry
- Bioimpedance sensing
- Electrocardiography (ECG)
- Skin temperature sensing
News & Updates
Awarded core intellectual property covering aspects of a multimodal sensing and analysis approach.
Recognized within the Asia-Pacific medtech innovation community.
Development-stage model performance derived from retrospective continuously-monitored cardiac, abdominal, and transplant cohorts (≈450 patients).
Prospective hospital studies with pre-specified endpoints are in progress to validate development-stage signals.
Awarded core intellectual property covering aspects of a multimodal sensing and analysis approach.
Recognized within the Asia-Pacific medtech innovation community.
Development-stage model performance derived from retrospective continuously-monitored cardiac, abdominal, and transplant cohorts (≈450 patients).
Prospective hospital studies with pre-specified endpoints are in progress to validate development-stage signals.